down arrow

Charles River Laboratories International, Inc.

  • Market Cap: Small Cap
  • Industry: Miscellaneous
  • ISIN: US1598641074
USD
184.04
-0.63 (-0.34%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

176.37186.72

52 Week

91.86202.72
Valuation
Technical
Day's Volume

CASH

992.77 k

Shareholding (Mar 2025)

FII

26.70%

Held by 313 FIIs

DII

20.71%

Held by 61 DIIs

Promoter

0.88%

How big is Charles River Laboratories International, Inc.?

22-Jun-2025

As of Jun 18, Charles River Laboratories International, Inc. has a market capitalization of 7,145.56 million, with net sales of 4,022.60 million and a net profit of -23.31 million over the latest four quarters. Shareholder's funds are 3,461.50 million, and total assets are 7,528.35 million.

Market Cap: As of Jun 18, Charles River Laboratories International, Inc. has a market capitalization of 7,145.56 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 4,022.60 million and a net profit of -23.31 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 3,461.50 million, while total assets were reported at 7,528.35 million.

Read More

What does Charles River Laboratories International, Inc. do?

22-Jun-2025

Charles River Laboratories International, Inc. is a contract research organization specializing in laboratory animal medicine and science, with net sales of $984 million and a market cap of approximately $7.15 billion as of March 2025. Key financial metrics include a P/E ratio of 22.00 and a return on equity of 9.99%.

Overview: <BR>Charles River Laboratories International, Inc. is an early-stage contract research company engaged in laboratory animal medicine and science, operating within the miscellaneous industry and mid-cap market segment.<BR><BR>Financial Snapshot: <BR>Net Sales: 984 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 26 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 7,145.56 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 22.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.71 <BR>Return on Equity: 9.99% <BR>Price to Book: 2.24<BR><BR>Contact Details: <BR>Address: 251 Ballardvale St, WILMINGTON MA: 01887-1096 <BR>Tel: 1 781 2226000 <BR>Website: https://www.criver.com/

Read More

Who are in the management team of Charles River Laboratories International, Inc.?

22-Jun-2025

As of March 2022, the management team of Charles River Laboratories includes Chairman and CEO James Foster, Lead Independent Director Dr. George Milne, and Independent Directors Dr. Nancy Andrews, Mr. Robert Bertolini, Mr. Stephen Chubb, and Director Mr. George Llado. They are responsible for guiding the company's strategic direction and operations.

As of March 2022, the management team of Charles River Laboratories International, Inc. includes the following individuals:<BR><BR>- Mr. James Foster, who serves as the Chairman of the Board, President, and Chief Executive Officer.<BR>- Dr. George Milne, who is the Lead Independent Director.<BR>- Mr. George Llado, who holds the position of Director.<BR>- Dr. Nancy Andrews, who is an Independent Director.<BR>- Mr. Robert Bertolini, who is also an Independent Director.<BR>- Mr. Stephen Chubb, who serves as an Independent Director. <BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Read More

Is Charles River Laboratories International, Inc. overvalued or undervalued?

20-Sep-2025

As of May 7, 2025, Charles River Laboratories is considered risky and overvalued with a P/E ratio of 22, significantly higher than peers, and has underperformed the S&P 500 with a year-to-date return of -14.96% and a 10-year return of -28.51%.

As of 7 May 2025, the valuation grade for Charles River Laboratories International, Inc. has moved from expensive to risky, indicating a shift in perception regarding its valuation. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 22, which is significantly higher than peers like ICON plc at 14.64 and Booz Allen Hamilton Holding Corp. at 15.81. Additionally, the EV to EBITDA ratio stands at 10.30, which is also above the industry average, suggesting that the company may not be justifying its price relative to earnings.<BR><BR>In comparison to the S&P 500, Charles River Laboratories has underperformed significantly over multiple periods, with a year-to-date return of -14.96% compared to the index's 12.22%, and a staggering 10-year return of -28.51% against the S&P 500's 231.64%. This stark contrast reinforces the notion that the stock may be overvalued in the current market environment.

Read More

Is Charles River Laboratories International, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Charles River Laboratories shows a mildly bullish trend with positive momentum from weekly and monthly MACD indicators, despite some caution from the KST and mixed signals from Bollinger Bands, while the stock has outperformed the S&P 500 recently but underperformed over the past five years.

As of 3 October 2025, the technical trend for Charles River Laboratories International, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. Daily moving averages are bullish, supporting the overall positive stance. However, the KST is mildly bearish on a weekly basis and bearish on a monthly basis, suggesting some caution. The Bollinger Bands show a mildly bullish signal weekly but a mildly bearish signal monthly, indicating mixed signals in volatility. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 19.02% and 6.68% respectively, but it has significantly underperformed over longer periods, including a -25.04% return over the past five years compared to the S&P 500's 100.56% gain. Overall, the current technical stance is mildly bullish, but with notable caution from some indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 11.49%

 
2

Flat results in Jun 25

3

Risky -

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 7,997 Million (Small Cap)

stock-summary
P/E

22.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.63

stock-summary
Return on Equity

8.57%

stock-summary
Price to Book

2.38

Revenue and Profits:
Net Sales:
1,032 Million
(Quarterly Results - Jun 2025)
Net Profit:
53 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.39%
0%
13.39%
6 Months
28.5%
0%
28.5%
1 Year
-7.68%
0%
-7.68%
2 Years
-8.26%
0%
-8.26%
3 Years
-17.34%
0%
-17.34%
4 Years
-48.5%
0%
-48.5%
5 Years
-22.48%
0%
-22.48%

Charles River Laboratories International, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Charles River Laboratories Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators

Charles River Laboratories Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators

Charles River Laboratories International, Inc. has recently seen a revision in its evaluation, with current stock price at $174.95. The company has experienced significant volatility over the past year, with a notable weekly return of 19.02%, although year-to-date performance shows a decline compared to the S&P 500.

Read More

Is Charles River Laboratories International, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Charles River Laboratories International, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. Daily moving averages are bullish, supporting the overall positive stance. However, the KST is mildly bearish on a weekly basis and bearish on a monthly basis, suggesting some caution. The Bollinger Bands show a mildly bullish signal weekly but a mildly bearish signal monthly, indicating mixed signals in volatility. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 19.02% and 6.68% respectively, but it has significantly underperformed over longer periods, including a -25.04% return over the past five years compared to the S&P 500's 100.56% gain. Overall, the current technical stance is mildly bullish, but w...

Read More

Is Charles River Laboratories International, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Charles River Laboratories International, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, and the daily moving averages are also bullish, indicating positive momentum. However, the monthly MACD is only mildly bullish, and the KST shows a bearish signal on both weekly and monthly timeframes. The Dow Theory reflects a mildly bullish stance on the weekly chart but is mildly bearish on the monthly chart. In terms of returns, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -3.94% compared to the S&P's 14.18%, and a one-year return of -6.47% versus the S&P's 17.82%. Overall, the current technical stance is mildly bullish, but the stock's performance relative to the benchmark remains a concern....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
7.95%
EBIT Growth (5y)
3.27%
EBIT to Interest (avg)
5.81
Debt to EBITDA (avg)
2.49
Net Debt to Equity (avg)
0.71
Sales to Capital Employed (avg)
0.69
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
11.49%
ROE (avg)
14.28%
Valuation key factors
Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
2.23
EV to EBIT
18.23
EV to EBITDA
10.30
EV to Capital Employed
1.72
EV to Sales
2.33
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
9.44%
ROE (Latest)
9.99%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 144 Schemes (51.7%)

Foreign Institutions

Held by 313 Foreign Institutions (26.7%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 4.87% vs -1.83% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 103.47% vs 112.12% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,032.10",
          "val2": "984.20",
          "chgp": "4.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "251.80",
          "val2": "218.90",
          "chgp": "15.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "30.00",
          "val2": "27.90",
          "chgp": "7.53%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-32.20",
          "val2": "-23.80",
          "chgp": "-35.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "52.70",
          "val2": "25.90",
          "chgp": "103.47%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "128.20%",
          "val2": "100.10%",
          "chgp": "2.81%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -1.92% vs 3.86% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -94.73% vs -2.48% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,050.00",
          "val2": "4,129.40",
          "chgp": "-1.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "928.60",
          "val2": "975.30",
          "chgp": "-4.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "126.30",
          "val2": "136.70",
          "chgp": "-7.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-352.40",
          "val2": "-43.90",
          "chgp": "-702.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "25.30",
          "val2": "480.40",
          "chgp": "-94.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "140.00%",
          "val2": "160.10%",
          "chgp": "-2.01%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
1,032.10
984.20
4.87%
Operating Profit (PBDIT) excl Other Income
251.80
218.90
15.03%
Interest
30.00
27.90
7.53%
Exceptional Items
-32.20
-23.80
-35.29%
Consolidate Net Profit
52.70
25.90
103.47%
Operating Profit Margin (Excl OI)
128.20%
100.10%
2.81%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 4.87% vs -1.83% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 103.47% vs 112.12% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
4,050.00
4,129.40
-1.92%
Operating Profit (PBDIT) excl Other Income
928.60
975.30
-4.79%
Interest
126.30
136.70
-7.61%
Exceptional Items
-352.40
-43.90
-702.73%
Consolidate Net Profit
25.30
480.40
-94.73%
Operating Profit Margin (Excl OI)
140.00%
160.10%
-2.01%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -1.92% vs 3.86% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -94.73% vs -2.48% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Charles River Laboratories International, Inc. stock-summary
stock-summary
Charles River Laboratories International, Inc.
Miscellaneous
Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.
Company Coordinates stock-summary
Company Details
251 Ballardvale St , WILMINGTON MA : 01887-1096
stock-summary
Tel: 1 781 2226000
stock-summary
https://www.criver.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."